Add-on migraine treatment for emergency room visits
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 19 and 75.
- You have a history of migraines or are in the emergency room with a migraine headache.
- Your migraine is not caused by a head injury, bleeding in the brain, infection, or tumor.
- You do not have serious heart or kidney disease or a condition like vasculitis that is actively being treated.
- You are not pregnant or at risk of pregnancy without birth control.
- You have not used eptinezumab or other anti-CGRP antibody treatments in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This trial tests whether a new class of migraine medicines, called gepants, can relieve migraine pain quickly when given in the emergency department. If you're having a migraine and haven't taken pain medication recently, you might be able to join.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This trial tests two fast-dissolving migraine medicines, Nurtec ODT and Maxalt MLT-ODT, in adults coming to the emergency room with a migraine. The goal is to see which one works better and faster for pain relief.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.